Barclays analyst Andrew Mok raised the firm’s price target on HCA Healthcare (HCA) to $551 from $494 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 report. HCA’s 2026 core growth of 6%-9% came in well ahead of expectations, and there remains earnings upside from both a late cycle Affordable Care Act subsidy extension and pending state directed payment programs, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Earnings Call: Growth Amid Policy Strain
- HCA Healthcare price target raised to $540 from $485 at BofA
- Early notable gainers among liquid option names on January 27th
- Morning Movers: Managed care group slide after CMS notice
- HCA Healthcare Posts Strong Q4 Results, Boosts Capital Returns